Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole.
about
Adjuvant endocrine therapy for early breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guidelinePersonalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013Late recurrences in early breast cancer: for whom and how long is endocrine therapy beneficial?Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2- breast cancer patients: results from the GEICAM 9906 trial.A highly-sensitive anti-Müllerian hormone assay improves analysis of ovarian function following chemotherapy for early breast cancer.Standard of care and controversies in the adjuvant endocrine treatment of hormone-responsive early breast cancer.Biology of breast cancer in young women.Breast Cancer Update 2014 - Focus on the Patient and the Tumour.Adjuvant hormonal therapy in premenopausal women with breast cancer.Adjuvant endocrine therapy in premenopausal women with breast cancer.From High-Throughput Microarray-Based Screening to Clinical Application: The Development of a Second Generation Multigene Test for Breast Cancer Prognosis.The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients.Luminal breast cancer: from biology to treatment.The UZ Leuven Policy for Extended Adjuvant Anti-estrogen Therapy in Women With Early Estrogen Receptor-Positive Breast Cancer.News on the medical treatment of young women with early-stage HER2-negative breast cancer.Ovarian Function Suppression in Premenopausal Women with Early-Stage Breast Cancer.Five or more years of adjuvant endocrine therapy in breast cancer: a meta-analysis of published randomised trials.Early participant-reported symptoms as predictors of adherence to anastrozole in the International Breast Cancer Intervention Studies II.Optimal duration of adjuvant endocrine therapy: how to apply the newest data.Adjuvant ovarian suppression for resected breast cancer: 2017 critical assessment.Optimal management of luminal breast cancer: how much endocrine therapy is long enough?
P2860
Q27002430-CFDB2DCA-C807-4403-B632-3BB86FEC0EBEQ30543788-4E601C57-C74A-4B49-8F92-4020B26415BCQ33684843-00909225-757C-45DB-AB10-7B5F5EBE9FC2Q33827057-3012F792-C3D4-4BC4-89DC-4E6ADEA5FCC3Q34199333-F97FA4A2-B591-4AC2-857B-C5A75B01B6F6Q34403564-0CE08E12-C093-4BD9-8DD1-A974A058B497Q35000798-75E17B96-77DA-4C6A-80A6-D0E38852CC04Q35180940-DA29EDDC-C34A-4191-B1D4-8EB9280FC88EQ36457989-DF673B44-0CCC-4F0C-8D4F-9D5E56DD320CQ36976772-81D95CB0-6573-4555-A07E-98D2588E9608Q37214217-16199CFD-C19B-41CE-9DCC-70620B7271EFQ37385272-D947354C-723E-47B5-8A73-B8E5788B37F8Q38123680-8448B38C-8458-472A-A062-0F731FD9CBE1Q38510960-BF6AA59F-5FA5-4CA6-884F-39B9D0DC88E0Q38870541-798058B5-7643-47DC-BD10-B927607BAB86Q38968531-E107808A-10CF-4B22-AE82-8BB7942D8F65Q47994905-A5E5902C-0CB2-436D-9975-09FDD56E8A7AQ48558036-8C3480D0-7569-4E88-97E7-2C6D45E12A3DQ49177338-4D854CA3-9A3C-406E-A826-06D4DCB3B412Q53538428-1CE40D9A-2511-4BA3-95DB-9A51D453BAB1Q55424072-70EB01D7-6032-4515-952A-6CB86903017A
P2860
Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole.
description
2012 nî lūn-bûn
@nan
2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Impact of premenopausal status ...... f extended adjuvant letrozole.
@ast
Impact of premenopausal status ...... f extended adjuvant letrozole.
@en
Impact of premenopausal status ...... f extended adjuvant letrozole.
@nl
type
label
Impact of premenopausal status ...... f extended adjuvant letrozole.
@ast
Impact of premenopausal status ...... f extended adjuvant letrozole.
@en
Impact of premenopausal status ...... f extended adjuvant letrozole.
@nl
prefLabel
Impact of premenopausal status ...... f extended adjuvant letrozole.
@ast
Impact of premenopausal status ...... f extended adjuvant letrozole.
@en
Impact of premenopausal status ...... f extended adjuvant letrozole.
@nl
P2093
P2860
P356
P1433
P1476
Impact of premenopausal status ...... f extended adjuvant letrozole.
@en
P2093
D A Cameron
K I Pritchard
L E Shepherd
N E Davidson
N J Robert
P2860
P304
P356
10.1093/ANNONC/MDS330
P577
2012-10-01T00:00:00Z